Kilitch Drugs (India) Ltd (KILITCH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 189669,
    "name": "Kilitch Drugs",
    "stock_name": "Kilitch Drugs",
    "full_name": "Kilitch Drugs (India) Ltd",
    "name_url": "stocks-analysis/kilitch-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "334.65",
    "chg": 10.8,
    "chgp": "3.33%",
    "dir": 1,
    "prev_price": "323.85",
    "mcapval": "577.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524500,
    "symbol": "KILITCH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE729D01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "13.26 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/kilitch-drugs-189669-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Kilitch Drugs technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kilitch-drugs-technically-bullish-or-bearish-3745319",
        "imagepath": "",
        "date": "2025-12-04 08:23:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Technical Trend Shift</strong></p>\n<p>As of 03 Dec 2025, Kilitch Drugs’ technical trend has transitioned from mildly bearish to outright bearish. This shift is underscored by several key technical indicators that suggest downward momentum in the near term. The Moving Average Convergence Divergence (MACD) on the weekly chart is firmly bearish, while the monthly MACD remains mildly bearish, indicating persistent selling pressure over both intermediate and longer time frames.</p>\n<p>The Relative Strength Index (RSI), a momentum oscillator, currently shows no clear signal on either weekly or monthly charts, implying a lack of strong directional momentum in terms of overbought or oversold conditions. However, the Bollinger Bands, which measure volatility and price levels relative to recent..."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-shares-shift-to-bearish-momentum-amid-technical-downgrade-3745177",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugsInd_technicaldot_3745177.png",
        "date": "2025-12-04 08:01:15",
        "description": "Kilitch Drugs (India) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. As the stock navigates a challenging phase within the Pharmaceuticals & Biotechnology sector, recent evaluation adjustments highlight evolving market dynamics and investor sentiment."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-technical-momentum-shifts-amid-mixed-market-signals-3742734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugsInd_technicaldot_3742734.png",
        "date": "2025-12-03 08:01:41",
        "description": "Kilitch Drugs (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market forces and analytical perspectives. Recent evaluation adjustments highlight a transition in price trends and technical indicators, offering investors a detailed view of the stock’s current positioning within a volatile market environment."
      },
      {
        "title": "Kilitch Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kilitch-drugs-downgraded-to-sell-by-marketsmojo-amid-weak-financial-and-technical-signals-3738120",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugs_mojoScore_3738120.png",
        "date": "2025-12-01 10:09:02",
        "description": "Kilitch Drugs has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial and technical developments. The pharmaceutical company’s assessment now reflects a more cautious outlook, influenced by a combination of flat financial trends, valuation considerations, and technical indicators."
      },
      {
        "title": "Is Kilitch Drugs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kilitch-drugs-overvalued-or-undervalued-3730110",
        "imagepath": "",
        "date": "2025-11-26 08:14:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics and Financial Health</strong></p>\n<p>Kilitch Drugs trades at a price-to-earnings (PE) ratio of approximately 22.3, which is moderate within the pharmaceutical industry context. Its price-to-book value stands at 2.32, indicating that the stock is priced at more than twice its book value, a common scenario for companies with growth potential in this sector. The enterprise value to EBITDA ratio of 19.36 suggests that the market values the company at nearly 19.4 times its earnings before interest, taxes, depreciation, and amortisation, a figure that is neither excessively high nor particularly low.</p>\n<p>Importantly, the company’s PEG ratio is notably low at 0.41, signalling that the stock’s price is relatively inexpensive compared to its earnings growth rate. This is a positi..."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-faces-bearish-momentum-amid-technical-downgrade-3727313",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KilitchDrugsInd_technicaldot_3727313.png",
        "date": "2025-11-25 08:01:27",
        "description": "Kilitch Drugs (India) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The pharmaceutical company’s stock price movements and technical parameters suggest evolving market sentiment amid broader sector dynamics."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-technical-momentum-shifts-amid-mixed-indicator-signals-3723621",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KilitchDrugsInd_technicaldot_3723621.png",
        "date": "2025-11-24 08:00:45",
        "description": "Kilitch Drugs (India) has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of indicator signals across multiple timeframes. Recent market data reveals a transition from a predominantly bearish stance to a mildly bearish outlook, underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages."
      },
      {
        "title": "Is Kilitch Drugs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kilitch-drugs-overvalued-or-undervalued-3709732",
        "imagepath": "",
        "date": "2025-11-18 08:20:09",
        "description": "As of 17 November 2025, the valuation grade for Kilitch Drugs has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 22.78, an EV to EBITDA of 19.76, and a PEG ratio of 0.42. These ratios suggest that Kilitch Drugs is positioned competitively within its industry.\n\nIn comparison to its peers, Kilitch Drugs holds a PE ratio that is significantly lower than Sun Pharma's 36.69 and Divi's Lab's 69.78, both of which are categorized as expensive. Meanwhile, it is on par with Aurobindo Pharma, which has a PE of 21.23, and slightly below Cipla's 22.81, both of which are rated as fair or attractive. Notably, Kilitch Drugs has outperformed the Sensex over the longer term, with a 3-year return of 117.32% compared to the Sensex's 37.57%. This performance, coupled with its fair valuation, su..."
      },
      {
        "title": "Is Kilitch Drugs technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kilitch-drugs-technically-bullish-or-bearish-3705761",
        "imagepath": "",
        "date": "2025-11-17 08:06:05",
        "description": "As of 14 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Kilitch Drugs is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish signal from Bollinger Bands on the weekly chart. Additionally, the KST and OBV are both bearish on the weekly, reinforcing the negative outlook. The stock's recent performance shows a significant decline of 5.81% over the past week, contrasting with a positive return from the Sensex...."
      }
    ],
    "total": 265,
    "sid": "189669",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/kilitch-drugs-india-189669"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "15-Jan-2026",
      "details": "We are submitting herewith the certificate under regulation74(5) received from our RTA",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Dec-2025",
      "details": "Trading window will be closed with effect from 1st January 2026 till expiry of 48 hours from the declaration of unaudited financial results of the company for the quarter ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Nov-2025",
      "details": "We are hereby submitting the copy publication of extract of financial results for the quarter ended 30th September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kilitch Drugs (India) Ltd has declared <strong>5%</strong> dividend, ex-date: 20 Sep 19",
          "dt": "2019-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Kilitch Drugs (India) Ltd has announced <strong>2:23</strong> rights issue, ex-date: 15 Jul 25",
          "dt": "2025-07-15",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Is Kilitch Drugs technically bullish or bearish?

2025-12-04 08:23:40

Recent Technical Trend Shift As of 03 Dec 2025, Kilitch Drugs’ technical trend has transitioned from mildly bearish to outright bearish. This shift is underscored by several key technical indicators that suggest downward momentum in the near term. The Moving Average Convergence Divergence (MACD) on the weekly chart is firmly bearish, while the monthly MACD remains mildly bearish, indicating persistent selling pressure over both intermediate and longer time frames. The Relative Strength Index (RSI), a momentum oscillator, currently shows no clear signal on either weekly or monthly charts, implying a lack of strong directional momentum in terms of overbought or oversold conditions. However, the Bollinger Bands, which measure volatility and price levels relative to recent...

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals

2025-12-04 08:01:15

Kilitch Drugs (India) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. As the stock navigates a challenging phase within the Pharmaceuticals & Biotechnology sector, recent evaluation adjustments highlight evolving market dynamics and investor sentiment.

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals

2025-12-03 08:01:41

Kilitch Drugs (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market forces and analytical perspectives. Recent evaluation adjustments highlight a transition in price trends and technical indicators, offering investors a detailed view of the stock’s current positioning within a volatile market environment.

Kilitch Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-12-01 10:09:02

Kilitch Drugs has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial and technical developments. The pharmaceutical company’s assessment now reflects a more cautious outlook, influenced by a combination of flat financial trends, valuation considerations, and technical indicators.

Is Kilitch Drugs overvalued or undervalued?

2025-11-26 08:14:05

Valuation Metrics and Financial Health Kilitch Drugs trades at a price-to-earnings (PE) ratio of approximately 22.3, which is moderate within the pharmaceutical industry context. Its price-to-book value stands at 2.32, indicating that the stock is priced at more than twice its book value, a common scenario for companies with growth potential in this sector. The enterprise value to EBITDA ratio of 19.36 suggests that the market values the company at nearly 19.4 times its earnings before interest, taxes, depreciation, and amortisation, a figure that is neither excessively high nor particularly low. Importantly, the company’s PEG ratio is notably low at 0.41, signalling that the stock’s price is relatively inexpensive compared to its earnings growth rate. This is a positi...

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals

2025-11-25 08:01:27

Kilitch Drugs (India) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The pharmaceutical company’s stock price movements and technical parameters suggest evolving market sentiment amid broader sector dynamics.

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Indicator Signals

2025-11-24 08:00:45

Kilitch Drugs (India) has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of indicator signals across multiple timeframes. Recent market data reveals a transition from a predominantly bearish stance to a mildly bearish outlook, underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages.

Is Kilitch Drugs overvalued or undervalued?

2025-11-18 08:20:09

As of 17 November 2025, the valuation grade for Kilitch Drugs has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 22.78, an EV to EBITDA of 19.76, and a PEG ratio of 0.42. These ratios suggest that Kilitch Drugs is positioned competitively within its industry. In comparison to its peers, Kilitch Drugs holds a PE ratio that is significantly lower than Sun Pharma's 36.69 and Divi's Lab's 69.78, both of which are categorized as expensive. Meanwhile, it is on par with Aurobindo Pharma, which has a PE of 21.23, and slightly below Cipla's 22.81, both of which are rated as fair or attractive. Notably, Kilitch Drugs has outperformed the Sensex over the longer term, with a 3-year return of 117.32% compared to the Sensex's 37.57%. This performance, coupled with its fair valuation, su...

Is Kilitch Drugs technically bullish or bearish?

2025-11-17 08:06:05

As of 14 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Kilitch Drugs is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish moving averages on the daily timeframe, and a bearish signal from Bollinger Bands on the weekly chart. Additionally, the KST and OBV are both bearish on the weekly, reinforcing the negative outlook. The stock's recent performance shows a significant decline of 5.81% over the past week, contrasting with a positive return from the Sensex....

View All News